@article{TCR29780,
author = {Alessandro Russo and Katherine A. Scilla and Christian Rolfo},
title = {Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial},
journal = {Translational Cancer Research},
volume = {8},
number = {Suppl 6},
year = {2019},
keywords = {},
abstract = {Treatment of advanced non-small cell lung cancer (NSCLC) has evolved considerably over the past two decades, with improved survival outcomes in a significant proportion of patients due to the development of new effective systemic therapies. The refinement of the therapeutic approach with a molecularly-based strategy has led to unprecedented results in selected patient populations harboring actionable oncogene drivers (~20–25% of all NSCLC patients).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/29780}
}